Pharmaceutical Contract Manufacturing Organization (CMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the pharmaceutical contract manufacturing organization market size is expected to grow from USD 184.44 billion in 2025 to USD 196.33 billion in 2026 and is forecast to reach USD 268.37 billion by 2031 at 6.45% CAGR over 2026-2031.

This report is Segmented by Service Type (API Manufacturing, and More), Drug Molecule Type (Small Molecule, Biologics, and Advanced Therapies), Scale of Operation (Clinical-Phase Manufacturing, and More), End User (Big Pharma, Generic Pharma, and More), Therapeutic Area (Oncology, Cardiovascular, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market Trends and Insights

Accelerating Small and Mid-Sized Pharma Outsourcing

Escalating compliance costs after the FDA's 2024 inspection overhaul elevated annual quality expenses by USD 2-5 million for mid-tier plants. The capital burden is steering resource-constrained sponsors toward strategic outsourcing across oncology and rare-disease portfolios. Contract manufacturers with integrated development and commercial capabilities benefit from predictable pipeline inflows, while hybrid fee-for-service and risk-sharing models are gaining traction.

Rising Biologics Pipeline Complexity

Multi-specific antibodies, antibody-drug conjugates, and autologous cell therapies require distinctive upstream cell culture, purification, and cold-chain infrastructure that few innovators can justify in-house. Samsung Biologics committed USD 2.4 billion in 2024 to expand single-use bioreactor capacity, signaling the scale of investment necessary for modern biologics production. Providers offering turnkey process development, viral clearance, and fill-finish services are now critical partners across biologics life cycles.

Capacity Bottlenecks in Fill-Finish Lines

Utilization above 85% and lead times exceeding 18 months for complex injectables limit CDMOs' ability to absorb new biologics programs. Sterile suites, advanced robotics, and serialization upgrades demand multi-year investments that delay relief, keeping short-term supply tight and potentially constraining near-term revenue realization.

Other drivers and restraints analyzed in the detailed report include:

1. Increasing Venture-Capital-Funded Virtual Biotechs
2. Demand Spike for High-Potency APIs (HPAPIs)
3. Escalating Regulatory Inspections and Remediation Costs

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

API manufacturing held 41.98% of pharmaceutical contract manufacturing organization market share in 2025, underpinning broad generic and branded drug demand. While small-molecule volumes stay dominant, biologics and HPAPI capacity additions are shifting revenue mix toward higher-value offerings. Clients increasingly seek integrated services that co-locate synthesis, purification, and final dosage manufacturing to eliminate supply handoffs.

Contractors offering both solid-dose and injectable dose formulation capture economies of scope. Digital serialization, continuous manufacturing, and predictive maintenance are reshaping operating cost curves, creating new competitive thresholds for entry. Integration with packaging services, particularly tamper-evident and track-and-trace solutions, further differentiates providers.

Small molecules still accounted for 56.85% of 2025 revenue, yet advanced therapies pushed the fastest expansion at an 8.22% CAGR. Viral vector production, cell expansion know-how, and cryogenic storage now dominate CAPEX priorities as developers chase one-time curative potential. The pharmaceutical contract manufacturing organization market size for advanced therapies is projected to broaden as more approved products transition from autologous to allogeneic processes, necessitating larger, standardized manufacturing runs.

Biologics occupy an intermediate growth position thanks to biosimilar adoption and novel antibody formats. Sustained investment across all molecule classes affirms the strategic imperative for CDMOs to maintain diversified technology portfolios rather than single-platform specialisms.

Complete Report Scope:

• By Service Type
  • API Manufacturing
    • Small Molecule
    • Large Molecule
    • High-Potency API (HPAPI)
  • FDF Development and Manufacturing
    • Solid Dose
    • Liquid Dose
    • Injectable Dose
  • Secondary Packaging
• By Drug Molecule Type
  • Small Molecule
  • Biologics
  • Advanced Therapies (Cell and Gene)
• By Scale of Operation
  • Clinical-Phase Manufacturing
  • Commercial-Scale Manufacturing
• By End User
  • Big Pharma
  • Generic Pharma
  • Emerging / Virtual Biotech
  • Specialty Pharma
• By Therapeutic Area
  • Oncology
  • Cardiovascular
  • Central Nervous System (CNS)
  • Infectious Disease
  • Other Therapeutic Areas
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Turkey
      • Rest of Middle East
    • Africa
      • South Africa
      • Kenya
      • Rest of Africa

Geography Analysis

North America held 39.85% of 2025 revenue, supported by strong intellectual property frameworks, proximity to drug innovators, and deep regulatory expertise. Ongoing investment in continuous manufacturing and cell-therapy infrastructure keeps the region a preferred partner location, though high labor costs limit incremental capacity additions.

Asia-Pacific is the fastest-growing region at a 8.91% CAGR, propelled by scale investments in China, India, and South Korea. Samsung Biologics' USD 2.4 billion build-out exemplifies regional commitment to state-of-the-art biologics capacity. Currency volatility and evolving quality expectations pose operational challenges, yet lower fixed costs and government incentives sustain its attractiveness within the pharmaceutical contract manufacturing organization market.

Europe enjoys stable demand thanks to established clusters in Germany, Ireland, Switzerland, and Scandinavia. Harmonized EMA regulations foster cross-border supply chains, particularly in advanced therapies. Middle East and Africa remain nascent but show potential as governments pursue medicine security and local manufacturing mandates.

1. Lonza Group Ltd.
2. Catalent Inc.
3. Thermo Fisher Scientific Inc.
4. Samsung Biologics Co. Ltd.
5. WuXi Biologics (Cayman) Inc.
6. Recipharm AB
7. Jubilant Pharmova Ltd.
8. Boehringer Ingelheim GmbH
9. Pfizer CentreOne (Pfizer Inc.)
10. Baxter International Inc. (Baxter BioPharma Solutions)
11. Aenova Holding GmbH
12. PCI Pharma Services
13. Cambrex Corporation
14. Siegfried Holding AG
15. Evonik Industries AG
16. Alcami Corporation
17. Ajinomoto Bio-Pharma Services
18. Eurofins CDMO Alphora Inc.
19. Famar SA
20. Tapemark LLC

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support